Advertisement

Antibacterial Drug Discovery: Perspective Insights

  • Iqbal Ahmad
  • Faizan Abul Qais
  • Samreen
  • Hussein Hasan Abulreesh
  • Shamim Ahmad
  • Kendra P. Rumbaugh
Chapter

Abstract

Over the last two decades, the development of new antibacterial drugs has been very limited due to many reasons. In light of the alarming situation of antimicrobial resistance (AMR), it is now vital to act promptly to develop new ways to combat the resistance problem through an integrated approach. Despite the slow progress of drug discovery by pharmaceutical companies, natural products have definitely provided an abundant source of new antibacterial leads. On the other hand, genomics- and proteomics-based drug discovery approaches have been more disappointing when it comes to the discovery of new antibacterials with novel modes of action. In the recent past, improved screening strategies and developments in target identification and validation, combinatorial chemistry, and the use of biochemical synthetic-based approaches have provided hope for the development of new antibacterial leads. Other approaches like novel anti-infective and anti-virulence target-based strategies such as quorum sensing, biofilm, virulence, and pathogenicity inhibitors are gaining popularity among drug discovery researchers. Similarly, nanotechnology-based drug delivery has seemingly unlimited application for improving the efficacy of antibiotics, where metallic and natural nanomaterials with antibacterial efficacy are under scrutiny for their possible therapeutic application. In this chapter, we aim to provide a brief overview and discussion of the potential for the various strategies mentioned above to combat drug-resistant bacterial infections.

Keywords

Antimicrobial resistance AMR Natural products Antibacterials Screening strategies Target identification Combinatorial approaches Efflux pump inhibitors Anti-infective approaches Nanoparticles Drug delivery 

References

  1. Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011). Phage treatment of human infections. Bacteriophage, 1, 66–85.  https://doi.org/10.4161/bact.1.2.15845.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Adalja, A. A., & Kellum, J. A. (2010). Clostridium difficile: Moving beyond antimicrobial therapy. Critical Care, 14, 320.  https://doi.org/10.1186/cc9249.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Ahmad, I., & Husain, F. (2014). Bacterial virulence, biofilm and quorum sensing as promising targets for anti-pathogenic drug discovery and the role of natural products. In J. Govil (Ed.), Biotechnology: Drug discovery (pp. 1–43). Houston: Studium Press LLC.Google Scholar
  4. Ahmad, I., Zahin, M., Aqil, F., et al. (2009). Novel approaches to combat drug-resistant bacteria. In New strategies combating bacterial infection (pp. 47–70). Weinheim: Wiley-VCH Verlag GmbH & KGaA.Google Scholar
  5. Allen, H. K., Levine, U. Y., Looft, T., et al. (2013). Treatment, promotion, commotion: Antibiotic alternatives in food-producing animals. Trends in Microbiology, 21, 114–119.  https://doi.org/10.1016/j.tim.2012.11.001.CrossRefPubMedGoogle Scholar
  6. Allen, H. K., Trachsel, J., Looft, T., & Casey, T. A. (2014). Finding alternatives to antibiotics. Annals of the New York Academy of Sciences, 1323, 91–100.  https://doi.org/10.1111/nyas.12468.CrossRefPubMedGoogle Scholar
  7. Amin, A. H., Subbaiah, T. V., & Abbasi, K. M. (1969). Berberine sulfate: Antimicrobial activity, bioassay, and mode of action. Canadian Journal of Microbiology, 15, 1067–1076.  https://doi.org/10.1139/m69-190.CrossRefPubMedGoogle Scholar
  8. Andes, D., Craig, W., Nielsen, L. A., & Kristensen, H. H. (2009). In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model. Antimicrobial Agents and Chemotherapy, 53, 3003–3009.  https://doi.org/10.1128/AAC.01584-08.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Andrade, F., Rafael, D., Videira, M., et al. (2013). Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Advanced Drug Delivery Reviews, 65, 1816–1827.  https://doi.org/10.1016/j.addr.2013.07.020.CrossRefPubMedGoogle Scholar
  10. Anthouard, R., & DiRita, V. J. (2015). Chemical biology applied to the study of bacterial pathogens. Infection and Immunity, 83, 456–469.  https://doi.org/10.1128/IAI.02021-14.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Arya, S. C. (2002). Global response to antimicrobial resistance. Bulletin of the World Health Organization, 80, 420.PubMedPubMedCentralGoogle Scholar
  12. Atterbury, R. J., Hobley, L., Till, R., et al. (2011). Effects of orally administered Bdellovibrio bacteriovorus on the well-being and Salmonella colonization of young chicks. Applied and Environmental Microbiology, 77, 5794–5803.  https://doi.org/10.1128/AEM.00426-11.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Ball, P. (2007). The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections. International Journal of Antimicrobial Agents, 30, 113–117.  https://doi.org/10.1016/j.ijantimicag.2007.07.037.CrossRefGoogle Scholar
  14. Balogh, B., Jones, J., Iriarte, F., & Momol, M. (2010). Phage therapy for plant disease control. Current Pharmaceutical Biotechnology, 11, 48–57.  https://doi.org/10.2174/138920110790725302.CrossRefPubMedGoogle Scholar
  15. Baltz, R. H. (2006). Highlights of the annual meeting of SIM, 2005. Journal of Industrial Microbiology & Biotechnology, 33, 475–475.  https://doi.org/10.1007/s10295-006-0133-0.CrossRefGoogle Scholar
  16. Baltz, R. H. (2008). Renaissance in antibacterial discovery from actinomycetes. Current Opinion in Pharmacology, 8, 557–563.  https://doi.org/10.1016/j.coph.2008.04.008.CrossRefPubMedGoogle Scholar
  17. Baptista, P. V., McCusker, M. P., Carvalho, A., et al. (2018). Nano-strategies to fight multidrug resistant bacteria—“A battle of the titans.”. Frontiers in Microbiology, 9, 1441.  https://doi.org/10.3389/fmicb.2018.01441.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Barker, J. J. (2006). Antibacterial drug discovery and structure-based design. Drug Discovery Today, 11, 391–404.  https://doi.org/10.1016/j.drudis.2006.03.001.CrossRefPubMedGoogle Scholar
  19. Baron, C. (2010). Antivirulence drugs to target bacterial secretion systems. Current Opinion in Microbiology, 13, 100–105.  https://doi.org/10.1016/j.mib.2009.12.003.CrossRefPubMedGoogle Scholar
  20. Bastos, M do C de F, Coutinho, B. G., & Coelho, M. L. V. (2010). Lysostaphin: A staphylococcal bacteriolysin with potential clinical applications. Pharmaceuticals, 3, 1139–1161.  https://doi.org/10.3390/ph3041139.CrossRefGoogle Scholar
  21. Bax, R., & Green, S. (2015). Antibiotics: The changing regulatory and pharmaceutical industry paradigm. The Journal of Antimicrobial Chemotherapy, 70, 1281–1284.  https://doi.org/10.1093/jac/dku572.CrossRefPubMedGoogle Scholar
  22. Bender, K. O., Garland, M., Ferreyra, J. A., et al. (2015). A small-molecule antivirulence agent for treating Clostridium difficile infection. Science Translational Medicine, 7, 306ra148.  https://doi.org/10.1126/scitranslmed.aac9103.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Biswas, B. (2002). Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infection and Immunity, 70, 204–210.  https://doi.org/10.1128/IAI.70.1.204-210.2002.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Brötz-Oesterhelt, H., & Sass, P. (2010). Postgenomic strategies in antibacterial drug discovery. Future Microbiology, 5, 1553–1579.  https://doi.org/10.2217/fmb.10.119.CrossRefPubMedGoogle Scholar
  25. Brown, E. D., & Wright, G. D. (2016). Antibacterial drug discovery in the resistance era. Nature, 529, 336–343.  https://doi.org/10.1038/nature17042.CrossRefPubMedGoogle Scholar
  26. Brussow, H. (2007). Phage therapy: The western perspective. In S. McGrath (Ed.), In bacteriophage: Genetics and microbiology (pp. 159–192). Norfolk: Academic.Google Scholar
  27. Burygin, G. L., Khlebtsov, B. N., Shantrokha, A. N., et al. (2009). On the enhanced antibacterial activity of antibiotics mixed with gold nanoparticles. Nanoscale Research Letters, 4, 794–801.  https://doi.org/10.1007/s11671-009-9316-8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Butler, M. S., & Buss, A. D. (2006). Natural products—The future scaffolds for novel antibiotics? Biochemical Pharmacology, 71, 919–929.  https://doi.org/10.1016/j.bcp.2005.10.012.CrossRefPubMedGoogle Scholar
  29. Cascioferro, S., Cusimano, M. G., & Schillaci, D. (2014). Antiadhesion agents against Gram-positive pathogens. Future Microbiology, 9, 1209–1220.  https://doi.org/10.2217/fmb.14.56.CrossRefPubMedGoogle Scholar
  30. Castro-Sánchez, E., Moore, L. S. P., Husson, F., & Holmes, A. H. (2016). What are the factors driving antimicrobial resistance? Perspectives from a public event in London, England. BMC Infectious Diseases, 16, 465.  https://doi.org/10.1186/s12879-016-1810-x.CrossRefPubMedPubMedCentralGoogle Scholar
  31. Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. Future Microbiology, 8, 769–783.  https://doi.org/10.2217/fmb.13.47.CrossRefPubMedGoogle Scholar
  32. Chen, Z., Moayeri, M., & Purcell, R. (2011). Monoclonal antibody therapies against anthrax. Toxins (Basel), 3, 1004–1019.  https://doi.org/10.3390/toxins3081004.CrossRefGoogle Scholar
  33. Clardy, J., Fischbach, M. A., & Walsh, C. T. (2006). New antibiotics from bacterial natural products. Nature Biotechnology, 24, 1541–1550.  https://doi.org/10.1038/nbt1266.CrossRefPubMedGoogle Scholar
  34. Collignon, P. (2012). The importance of a one health approach to preventing the development and spread of antibiotic resistance. In One health: The human-animal-environment interfaces in emerging infectious diseases (pp. 19–36). Heidelberg: Springer.CrossRefGoogle Scholar
  35. CORD-WINDER. (1862). Patent No. 34,954.Google Scholar
  36. Cotter, P. D., Ross, R. P., & Hill, C. (2013). Bacteriocins—A viable alternative to antibiotics? Nature Reviews. Microbiology, 11, 95–105.  https://doi.org/10.1038/nrmicro2937.CrossRefPubMedGoogle Scholar
  37. Dale, G. E., Broger, C., D’Arcy, A., et al. (1997). A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance 1 1 edited by T.Richmond. Journal of Molecular Biology, 266, 23–30.  https://doi.org/10.1006/jmbi.1996.0770.CrossRefPubMedGoogle Scholar
  38. Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews, 74, 417–433.  https://doi.org/10.1128/MMBR.00016-10.CrossRefPubMedGoogle Scholar
  39. Dwidar, M., Monnappa, A. K., & Mitchell, R. J. (2012). The dual probiotic and antibiotic nature of Bdellovibrio bacteriovorus. BMB Reports, 45, 71–78.  https://doi.org/10.5483/BMBRep.2012.45.2.71.CrossRefPubMedGoogle Scholar
  40. Dzidic, S., & Bedeković, V. (2003). Horizontal gene transfer-emerging multidrug resistance in hospital bacteria. Acta Pharmacologica Sinica, 24, 519–526.PubMedGoogle Scholar
  41. Fernandes, P. (2006). Antibacterial discovery and development—The failure of success? Nature Biotechnology, 24, 1497–1503.  https://doi.org/10.1038/nbt1206-1497.CrossRefPubMedGoogle Scholar
  42. Fleming, D., & Rumbaugh, K. (2017). Approaches to dispersing medical biofilms. Microorganisms, 5, 15.  https://doi.org/10.3390/microorganisms5020015.CrossRefPubMedCentralGoogle Scholar
  43. Fleming, D., & Rumbaugh, K. (2018). The consequences of biofilm dispersal on the host. Scientific Reports, 8, 10738.  https://doi.org/10.1038/s41598-018-29121-2.CrossRefPubMedPubMedCentralGoogle Scholar
  44. Fleming, D., Chahin, L., & Rumbaugh, K. (2016). Glycoside hydrolases degrade polymicrobial bacterial biofilms in wounds. Antimicrobial Agents and Chemotherapy, 61, AAC.01998-16.  https://doi.org/10.1128/AAC.01998-16.CrossRefGoogle Scholar
  45. Freiberg, C., Brötz-Oesterhelt, H., & Labischinski, H. (2004). The impact of transcriptome and proteome analyses on antibiotic drug discovery. Current Opinion in Microbiology, 7, 451–459.  https://doi.org/10.1016/j.mib.2004.08.010.CrossRefPubMedGoogle Scholar
  46. Gallant, P., Finn, J., Keith, D., & Wendler, P. (2000). The identification of quality antibacterial drug discovery targets: A case study with aminoacyl-tRNA synthetases. Emerging Therapeutic Targets, 4, 1–9.  https://doi.org/10.1517/14728222.4.1.1.CrossRefGoogle Scholar
  47. Gholipourmalekabadi, M., Mobaraki, M., Ghaffari, M., et al. (2017). Targeted drug delivery based on gold nanoparticle derivatives. Current Pharmaceutical Design, 23, 2918–2929.  https://doi.org/10.2174/1381612823666170419105413.CrossRefPubMedGoogle Scholar
  48. Goodridge, L. D., & Bisha, B. (2011). Phage-based biocontrol strategies to reduce foodborne pathogens in foods. Bacteriophage, 1, 130–137.  https://doi.org/10.4161/bact.1.3.17629.CrossRefPubMedPubMedCentralGoogle Scholar
  49. Guiton, P. S., Cusumano, C. K., Kline, K. A., et al. (2012). Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrobial Agents and Chemotherapy, 56, 4738–4745.  https://doi.org/10.1128/AAC.00447-12.CrossRefPubMedPubMedCentralGoogle Scholar
  50. Hagihara, M., Crandon, J. L., & Nicolau, D. P. (2012). The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms. Expert Opinion on Drug Safety, 11, 221–233.  https://doi.org/10.1517/14740338.2012.632631.CrossRefGoogle Scholar
  51. Hajipour, M. J., Fromm, K. M., Akbar Ashkarran, A., et al. (2012). Antibacterial properties of nanoparticles. Trends in Biotechnology, 30, 499–511.  https://doi.org/10.1016/j.tibtech.2012.06.004.CrossRefPubMedGoogle Scholar
  52. Hamoud, R., Zimmermann, S., Reichling, J., & Wink, M. (2014). Synergistic interactions in two-drug and three-drug combinations (thymol, EDTA and vancomycin) against multi drug resistant bacteria including E. coli. Phytomedicine, 21, 443–447.  https://doi.org/10.1016/j.phymed.2013.10.016.CrossRefGoogle Scholar
  53. Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015). The re-emergence of natural products for drug discovery in the genomics era. Nature Reviews. Drug Discovery, 14, 111–129.  https://doi.org/10.1038/nrd4510.CrossRefPubMedGoogle Scholar
  54. He, H., Williamson, R. T., Shen, B., et al. (2002). Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. Journal of the American Chemical Society, 124, 9729–9736.  https://doi.org/10.1021/ja020257s.CrossRefPubMedGoogle Scholar
  55. Hemeg, H. (2017). Nanomaterials for alternative antibacterial therapy. International Journal of Nanomedicine, 12, 8211–8225.  https://doi.org/10.2147/IJN.S132163.CrossRefPubMedPubMedCentralGoogle Scholar
  56. Heras, B., Scanlon, M. J., & Martin, J. L. (2015). Targeting virulence not viability in the search for future antibacterials. British Journal of Clinical Pharmacology, 79, 208–215.  https://doi.org/10.1111/bcp.12356.CrossRefPubMedPubMedCentralGoogle Scholar
  57. Hsieh, P.-C., Siegel, S. A., Rogers, B., et al. (1998). Bacteria lacking a multidrug pump: A sensitive tool for drug discovery. Proceedings of the National Academy of Sciences, 95, 6602–6606.  https://doi.org/10.1073/pnas.95.12.6602.CrossRefGoogle Scholar
  58. Huang, Y., Yu, F., Park, Y.-S., et al. (2010). Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials, 31, 9086–9091.  https://doi.org/10.1016/j.biomaterials.2010.08.046.CrossRefPubMedPubMedCentralGoogle Scholar
  59. Huh, A. J., & Kwon, Y. J. (2011). “Nanoantibiotics”: A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. Journal of Controlled Release, 156, 128–145.  https://doi.org/10.1016/j.jconrel.2011.07.002.CrossRefPubMedGoogle Scholar
  60. Ippolito, J., Wang, D., & Chen, S. (2009). Novel antibiotic classes to treat Gram-negative infections. Annual interscience conference on antimicrobial agents and chemotherapy (ICAAC). California, p Poster F2–861.Google Scholar
  61. Johnson, R. P., Gyles, C. L., Huff, W. E., et al. (2008). Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. Animal Health Research Reviews, 9, 201–215.  https://doi.org/10.1017/S1466252308001576.CrossRefPubMedGoogle Scholar
  62. Joshi-Navare, K., & Prabhune, A. (2013). A biosurfactant-sophorolipid acts in synergy with antibiotics to enhance their efficiency. BioMed Research International, 2013, 1–8.  https://doi.org/10.1155/2013/512495.CrossRefGoogle Scholar
  63. Kadouri, D. E., To, K., Shanks, R. M. Q., & Doi, Y. (2013). Predatory bacteria: A potential ally against multidrug-resistant Gram-negative pathogens. PLoS One, 8, e63397.  https://doi.org/10.1371/journal.pone.0063397.CrossRefPubMedPubMedCentralGoogle Scholar
  64. Kaeberlein, T. (2002). Isolating “uncultivable” microorganisms in pure culture in a simulated natural environment. Science (80- ), 296, 1127–1129.  https://doi.org/10.1126/science.1070633.CrossRefGoogle Scholar
  65. Kaier, K., Wilson, C., Chalkley, M., et al. (2008). Health and economic impacts of antibiotic resistance in European hospitals—Outlook on the BURDEN project. Infection, 36, 492–494.  https://doi.org/10.1007/s15010-008-7453-0.CrossRefPubMedGoogle Scholar
  66. Kalia, V. C. (2013). Quorum sensing inhibitors: An overview. Biotechnology Advances, 31, 224–245.  https://doi.org/10.1016/j.biotechadv.2012.10.004.CrossRefPubMedGoogle Scholar
  67. Kalia, V. C., Wood, T. K., & Kumar, P. (2014). Evolution of resistance to quorum-sensing inhibitors. Microbial Ecology, 68, 13–23.  https://doi.org/10.1007/s00248-013-0316-y.CrossRefPubMedGoogle Scholar
  68. Kalle, A. M., & Rizvi, A. (2011). Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrobial Agents and Chemotherapy, 55, 439–442.  https://doi.org/10.1128/AAC.00735-10.CrossRefPubMedPubMedCentralGoogle Scholar
  69. Khameneh, B., Diab, R., Ghazvini, K., & Fazly Bazzaz, B. S. (2016). Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microbial Pathogenesis, 95, 32–42.  https://doi.org/10.1016/j.micpath.2016.02.009.CrossRefPubMedPubMedCentralGoogle Scholar
  70. Khan, M. S., Qais, F. A., & Ahmad, I. (2018). Quorum sensing interference by natural products from medicinal plants: Significance in combating bacterial infection. In Biotechnological applications of quorum sensing inhibitors (pp. 417–445). Singapore: Springer Singapore.CrossRefGoogle Scholar
  71. Kohanski, M. A., Dwyer, D. J., & Collins, J. J. (2010). How antibiotics kill bacteria: From targets to networks. Nature Reviews. Microbiology, 8, 423–435.  https://doi.org/10.1038/nrmicro2333.CrossRefPubMedPubMedCentralGoogle Scholar
  72. Koskella, B., & Meaden, S. (2013). Understanding bacteriophage specificity in natural microbial communities. Viruses, 5, 806–823.  https://doi.org/10.3390/v5030806.CrossRefPubMedPubMedCentralGoogle Scholar
  73. Lambert, C., & Sockett, R. E. (2013). Nucleases in Bdellovibrio bacteriovorus contribute towards efficient self-biofilm formation and eradication of preformed prey biofilms. FEMS Microbiology Letters, 340, 109–116.  https://doi.org/10.1111/1574-6968.12075.CrossRefPubMedPubMedCentralGoogle Scholar
  74. Langeveld, W. T., Veldhuizen, E. J. A., & Burt, S. A. (2014). Synergy between essential oil components and antibiotics: A review. Critical Reviews in Microbiology, 40, 76–94.  https://doi.org/10.3109/1040841X.2013.763219.CrossRefPubMedGoogle Scholar
  75. Laxminarayan, R., Duse, A., Wattal, C., et al. (2013). Antibiotic resistance—The need for global solutions. The Lancet Infectious Diseases, 13, 1057–1098.  https://doi.org/10.1016/S1473-3099(13)70318-9.CrossRefPubMedGoogle Scholar
  76. Lee, S. H., Shoop, W., Michael, B., et al. (2006). In vivo evaluation of drug lead candidates by intravenous continuous infusion. Protocol Exchange.  https://doi.org/10.1038/nprot.2006.133.
  77. Lewis, K. (2013). Platforms for antibiotic discovery. Nature Reviews. Drug Discovery, 12, 371–387.  https://doi.org/10.1038/nrd3975.CrossRefPubMedGoogle Scholar
  78. Lewis, K., & Ausubel, F. M. (2006). Prospects for plant-derived antibacterials. Nature Biotechnology, 24, 1504–1507.  https://doi.org/10.1038/nbt1206-1504.CrossRefPubMedGoogle Scholar
  79. Lomovskaya, O., Warren, M. S., Lee, A., et al. (2001). Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy. Antimicrobial Agents and Chemotherapy, 45, 105–116.  https://doi.org/10.1128/AAC.45.1.105-116.2001.CrossRefPubMedPubMedCentralGoogle Scholar
  80. Lopez, E. L., Contrini, M. M., Glatstein, E., et al. (2010). Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against shiga-like toxin 2 in healthy adults and in pediatric patients infected with shiga-like toxin-producing Escherichia coli. Antimicrobial Agents and Chemotherapy, 54, 239–243.  https://doi.org/10.1128/AAC.00343-09.CrossRefPubMedGoogle Scholar
  81. Michael, C. A., Dominey-Howes, D., & Labbate, M. (2014). The antimicrobial resistance crisis: Causes, consequences, and management. Frontiers in Public Health, 2, 145.  https://doi.org/10.3389/fpubh.2014.00145.CrossRefPubMedPubMedCentralGoogle Scholar
  82. Międzybrodzki, R., Borysowski, J., Weber-Dąbrowska, B., et al. (2012). Clinical aspects of phage therapy. Advances in Virus Research, 83, 73–121.CrossRefGoogle Scholar
  83. Miller, A. (2008). Alternate strategies in antibacterial discovery. Visiongain conference on Re-emerging infectious diseases. London.Google Scholar
  84. Mitchison, D., & Davies, G. (2012). The chemotherapy of tuberculosis: Past, present and future [State of the art]. The International Journal of Tuberculosis and Lung Disease, 16, 724–732.  https://doi.org/10.5588/ijtld.12.0083.CrossRefPubMedPubMedCentralGoogle Scholar
  85. Muscholl-Silberhorn, A., Thiel, V., & Imhoff, J. F. (2008). Abundance and bioactivity of cultured sponge-associated bacteria from the Mediterranean sea. Microbial Ecology, 55, 94–106.  https://doi.org/10.1007/s00248-007-9255-9.CrossRefPubMedGoogle Scholar
  86. Mygind, P. H., Fischer, R. L., Schnorr, K. M., et al. (2005). Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature, 437, 975–980.  https://doi.org/10.1038/nature04051.CrossRefPubMedGoogle Scholar
  87. Naghmouchi, K., Belguesmia, Y., Baah, J., et al. (2011). Antibacterial activity of class I and IIa bacteriocins combined with polymyxin E against resistant variants of Listeria monocytogenes and Escherichia coli. Research in Microbiology, 162, 99–107.  https://doi.org/10.1016/j.resmic.2010.09.014.CrossRefPubMedGoogle Scholar
  88. NCBI. (2019). National center for biotechnology information. https://www.ncbi.nlm.nih.gov/genome/browse/#!/overview/
  89. Nett, M., & König, G. M. (2007). The chemistry of gliding bacteria. Natural Product Reports, 24, 1245.  https://doi.org/10.1039/b612668p.CrossRefPubMedGoogle Scholar
  90. Newman, D. J., Cragg, G. M., & Snader, K. M. (2000). The influence of natural products upon drug discovery (Antiquity to late 1999). Natural Product Reports, 17, 215–234.  https://doi.org/10.1039/a902202c.CrossRefPubMedGoogle Scholar
  91. Nicolaou, K. C., Chen, J. S., Edmonds, D. J., & Estrada, A. A. (2009). Recent advances in the chemistry and biology of naturally occurring antibiotics. Angewandte Chemie International Edition, 48, 660–719.  https://doi.org/10.1002/anie.200801695.CrossRefPubMedGoogle Scholar
  92. Pasternak, Z., Pietrokovski, S., Rotem, O., et al. (2013). By their genes ye shall know them: Genomic signatures of predatory bacteria. The ISME Journal, 7, 756–769.  https://doi.org/10.1038/ismej.2012.149.CrossRefPubMedGoogle Scholar
  93. Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007). Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nature Reviews. Drug Discovery, 6, 29–40.  https://doi.org/10.1038/nrd2201.CrossRefPubMedPubMedCentralGoogle Scholar
  94. Peppard, W. J., & Schuenke, C. D. (2008). Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Current Opinion in Investigational Drugs, 9, 210–225.PubMedGoogle Scholar
  95. Perron, G. G., Kryazhimskiy, S., Rice, D. P., & Buckling, A. (2012). Multidrug therapy and evolution of antibiotic resistance: When order matters. Applied and Environmental Microbiology, 78, 6137–6142.  https://doi.org/10.1128/AEM.01078-12.CrossRefPubMedPubMedCentralGoogle Scholar
  96. Prestinaci, F., Pezzotti, P., & Pantosti, A. (2015). Antimicrobial resistance: A global multifaceted phenomenon. Pathogens and Global Health, 109, 309–318.  https://doi.org/10.1179/2047773215Y.0000000030.CrossRefPubMedPubMedCentralGoogle Scholar
  97. Projan, S. J. (2003). Why is big pharma getting out of antibacterial drug discovery? Current Opinion in Microbiology, 6, 427–430.  https://doi.org/10.1016/j.mib.2003.08.003.CrossRefPubMedGoogle Scholar
  98. Qais, F. A., Samreen, & Ahmad, I. (2018). Broad-spectrum inhibitory effect of green synthesised silver nanoparticles from Withania somnifera (L.) on microbial growth, biofilm and respiration: A putative mechanistic approach. IET Nanobiotechnology, 12, 325–335.  https://doi.org/10.1049/iet-nbt.2017.0193.CrossRefGoogle Scholar
  99. Qais, F. A., Khan, M. S., & Ahmad, I. (2019). Broad-spectrum quorum sensing and biofilm inhibition by green tea against Gram-negative pathogenic bacteria: Deciphering the role of phytocompounds through molecular modelling. Microbial Pathogenesis, 126, 379–392.  https://doi.org/10.1016/j.micpath.2018.11.030.CrossRefPubMedGoogle Scholar
  100. Rai, M., Ingle, A. P., Gaikwad, S., et al. (2016). Nanotechnology based anti-infectives to fight microbial intrusions. Journal of Applied Microbiology, 120, 527–542.  https://doi.org/10.1111/jam.13010.CrossRefPubMedGoogle Scholar
  101. Rasko, D. A., & Sperandio, V. (2010). Anti-virulence strategies to combat bacteria-mediated disease. Nature Reviews. Drug Discovery, 9, 117–128.  https://doi.org/10.1038/nrd3013.CrossRefPubMedGoogle Scholar
  102. Roca, I., Akova, M., Baquero, F., et al. (2015). The global threat of antimicrobial resistance: Science for intervention. New Microbes and New Infections, 6, 22–29.  https://doi.org/10.1016/j.nmni.2015.02.007.CrossRefPubMedPubMedCentralGoogle Scholar
  103. Rudramurthy, G., Swamy, M., Sinniah, U., & Ghasemzadeh, A. (2016). Nanoparticles: Alternatives against drug-resistant pathogenic microbes. Molecules, 21, 836.  https://doi.org/10.3390/molecules21070836.CrossRefPubMedCentralGoogle Scholar
  104. Ruzin, A., Singh, G., Severin, A., et al. (2004). Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant Gram-positive bacteria. Antimicrobial Agents and Chemotherapy, 48, 728–738.  https://doi.org/10.1128/AAC.48.3.728-738.2004.CrossRefPubMedPubMedCentralGoogle Scholar
  105. Schneider, P., Hawser, S., & Islam, K. (2003). Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorganic & Medicinal Chemistry Letters, 13, 4217–4221.  https://doi.org/10.1016/j.bmcl.2003.07.023.CrossRefGoogle Scholar
  106. Severina, I. I., Muntyan, M. S., Lewis, K., & Skulachev, V. P. (2001). Transfer of cationic antibacterial agents berberine, palmatine, and benzalkonium through bimolecular planar phospholipid film and Staphylococcus aureus membrane. IUBMB Life (International Union of Biochemistry and Molecular Biology), 52, 321–324.  https://doi.org/10.1080/152165401317291183.CrossRefGoogle Scholar
  107. Shokri, D., Zaghian, S., Khodabakhsh, F., et al. (2014). Antimicrobial activity of a UV-stable bacteriocin-like inhibitory substance (BLIS) produced by Enterococcus faecium strain DSH20 against vancomycin-resistant Enterococcus (VRE) strains. Journal of Microbiology, Immunology, and Infection, 47, 371–376.  https://doi.org/10.1016/j.jmii.2013.05.004.CrossRefPubMedGoogle Scholar
  108. Silver, L. L. (2011). Challenges of antibacterial discovery. Clinical Microbiology Reviews, 24, 71–109.  https://doi.org/10.1128/CMR.00030-10.CrossRefPubMedPubMedCentralGoogle Scholar
  109. Singh, S. B., & Barrett, J. F. (2006). Empirical antibacterial drug discovery—Foundation in natural products. Biochemical Pharmacology, 71, 1006–1015.  https://doi.org/10.1016/j.bcp.2005.12.016.CrossRefPubMedGoogle Scholar
  110. Singh, M. P., Petersen, P. J., Weiss, W. J., et al. (2003). Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: Antibacterial and mechanistic activities. Antimicrobial Agents and Chemotherapy, 47, 62–69.  https://doi.org/10.1128/AAC.47.1.62-69.2003.CrossRefPubMedPubMedCentralGoogle Scholar
  111. Smith, R., & Coast, J. (2002). Antimicrobial resistance: A global response. Bulletin of the World Health Organization, 80, 126–133.PubMedPubMedCentralGoogle Scholar
  112. Smith, H. W., & Huggins, M. B. (1982). Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics. Microbiology, 128, 307–318.  https://doi.org/10.1099/00221287-128-2-307.CrossRefGoogle Scholar
  113. Snyder, A. B., & Worobo, R. W. (2014). Chemical and genetic characterization of bacteriocins: Antimicrobial peptides for food safety. Journal of the Science of Food and Agriculture, 94, 28–44.  https://doi.org/10.1002/jsfa.6293.CrossRefPubMedGoogle Scholar
  114. Sockett, R. E., & Lambert, C. (2004). Bdellovibrio as therapeutic agents: A predatory renaissance? Nature Reviews. Microbiology, 2, 669–675.  https://doi.org/10.1038/nrmicro959.CrossRefPubMedGoogle Scholar
  115. Steadman, D., Lo, A., Waksman, G., & Remaut, H. (2014). Bacterial surface appendages as targets for novel antibacterial therapeutics. Future Microbiology, 9, 887–900.  https://doi.org/10.2217/fmb.14.46.CrossRefPubMedGoogle Scholar
  116. Stermitz, F. R., Lorenz, P., Tawara, J. N., et al. (2000). Synergy in a medicinal plant: Antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proceedings of the National Academy of Sciences, 97, 1433–1437.  https://doi.org/10.1073/pnas.030540597.CrossRefGoogle Scholar
  117. Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012). Combination therapy for treatment of infections with Gram-negative bacteria. Clinical Microbiology Reviews, 25, 450–470.  https://doi.org/10.1128/CMR.05041-11.CrossRefPubMedPubMedCentralGoogle Scholar
  118. Taylor, J., Hafner, M., Yerushalmi, E., et al. (2014). Estimating the economic costs of antimicrobial resistance. Model and results. Cambridge: RAND Corporation.Google Scholar
  119. Tillotson, G. S., & Zinner, S. H. (2017). Burden of antimicrobial resistance in an era of decreasing susceptibility. Expert Review of Anti-Infective Therapy, 15, 663–676.  https://doi.org/10.1080/14787210.2017.1337508.CrossRefPubMedGoogle Scholar
  120. Totsika, M. (2016). Benefits and challenges of antivirulence antimicrobials at the dawn of the post-antibiotic era. Drug Delivery Letters, 6, 30–37.  https://doi.org/10.2174/2210303106666160506120057.CrossRefGoogle Scholar
  121. USCDC. (2013). Centers for disease control and prevention. Antibiotic resistance threats in the United States. Stockholm: ECDC.Google Scholar
  122. Van Essche, M., Quirynen, M., Sliepen, I., et al. (2011). Killing of anaerobic pathogens by predatory bacteria. Molecular Oral Microbiology, 26, 52–61.  https://doi.org/10.1111/j.2041-1014.2010.00595.x.CrossRefPubMedGoogle Scholar
  123. Vidhyasagar, V., & Jeevaratnam, K. (2013). Bacteriocin activity against various pathogens produced by Pediococcus pentosaceus VJ13 isolated from Idly batter. Biomedical Chromatography, 27, 1497–1502.  https://doi.org/10.1002/bmc.2948.CrossRefPubMedGoogle Scholar
  124. von Nussbaum, F., Brands, M., Hinzen, B., et al. (2006). Antibacterial natural products in medicinal chemistry—Exodus or revival? Angewandte Chemie International Edition, 45, 5072–5129.  https://doi.org/10.1002/anie.200600350.CrossRefGoogle Scholar
  125. Wang, J., Soisson, S. M., Young, K., et al. (2006). Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature, 441, 358–361.  https://doi.org/10.1038/nature04784.CrossRefPubMedGoogle Scholar
  126. Wang, L., Hu, C., & Shao, L. (2017). The antimicrobial activity of nanoparticles: Present situation and prospects for the future. International Journal of Nanomedicine, 12, 1227–1249.  https://doi.org/10.2147/IJN.S121956.CrossRefPubMedPubMedCentralGoogle Scholar
  127. Wimberly, B. T. (2009). The use of ribosomal crystal structures in antibiotic drug design. Current Opinion in Investigational Drugs, 10, 750–765.PubMedGoogle Scholar
  128. Wolska, K. I., Grześ, K., & Kurek, A. (2012). Synergy between novel antimicrobials and conventional antibiotics or bacteriocins. Polish Journal of Microbiology, 61, 95–104.PubMedGoogle Scholar
  129. Worthington, R. J., & Melander, C. (2013a). Combination approaches to combat multidrug-resistant bacteria. Trends in Biotechnology, 31, 177–184.  https://doi.org/10.1016/j.tibtech.2012.12.006.CrossRefPubMedPubMedCentralGoogle Scholar
  130. Worthington, R. J., & Melander, C. (2013b). Overcoming resistance to β-lactam antibiotics. The Journal of Organic Chemistry, 78, 4207–4213.  https://doi.org/10.1021/jo400236f.CrossRefPubMedPubMedCentralGoogle Scholar
  131. Young, K., Jayasuriya, H., Ondeyka, J. G., et al. (2006). Discovery of FabH/FabF inhibitors from natural products. Antimicrobial Agents and Chemotherapy, 50, 519–526.  https://doi.org/10.1128/AAC.50.2.519-526.2006.CrossRefPubMedPubMedCentralGoogle Scholar
  132. Zaidi, S., Misba, L., & Khan, A. U. (2017). Nano-therapeutics: A revolution in infection control in post antibiotic era. Nanomedicine: Nanotechnology, Biology, and Medicine, 13, 2281–2301.  https://doi.org/10.1016/j.nano.2017.06.015.CrossRefGoogle Scholar
  133. Zarrilli, R., Pournaras, S., Giannouli, M., & Tsakris, A. (2013). Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. International Journal of Antimicrobial Agents, 41, 11–19.  https://doi.org/10.1016/j.ijantimicag.2012.09.008.CrossRefPubMedGoogle Scholar
  134. Zendo, T. (2013). Screening and characterization of novel bacteriocins from lactic acid bacteria. Bioscience, Biotechnology, and Biochemistry, 77, 893–899.  https://doi.org/10.1271/bbb.130014.CrossRefPubMedGoogle Scholar
  135. Zhang, X. (2010). Human in check: New threat from superbugs equipped with NDM-1. Protein & Cell, 1, 1051–1052.  https://doi.org/10.1007/s13238-010-0134-7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Iqbal Ahmad
    • 1
  • Faizan Abul Qais
    • 1
  • Samreen
    • 1
  • Hussein Hasan Abulreesh
    • 2
  • Shamim Ahmad
    • 3
  • Kendra P. Rumbaugh
    • 4
  1. 1.Department of Agricultural Microbiology, Faculty of Agricultural SciencesAligarh Muslim UniversityAligarhIndia
  2. 2.Department of Biology, Faculty of Applied ScienceUmm Al-Qura UniversityMakkahKingdom of Saudi Arabia
  3. 3.Division of Microbiology, Institute of Ophthalmology, JN Medical CollegeAligarh Muslim UniversityAligarhIndia
  4. 4.School of MedicineTexas Tech University Health Sciences CenterLubbockUSA

Personalised recommendations